Ingram’s: A Genetic Condition

 1 minute Ingram's, the leading business publication in Missouri and Kansas for more than 40 years.

Kansas City research hospitals and clinics are exploring building blocks of life in broad-based effort to improve outcomes and extend lives.

Ingram's talked to Dr. Marc Roth and Blake Buzard with Saint Luke's Hospital Center for Precision Oncology about the rapid pace of advances in precision medicine.

“If you look at just 2024, with the new oncology drug approvals by the FDA, about half of them were for targeted therapies and precision therapeutics. That number grows each year,” said Dr. Roth. “It’s not just the drug development, but also the ways we identify who will benefit from these drugs. With sequencing platforms or testing on patients with advanced cancer, as those become more sensitive and are better able to detect specific molecular aberrations, locations and numbers of genes they detect, we’re able to find more patients with these targetable aberrations and find new ones.”

Read the full Ingram’s article: A Genetic Condition.